Composition and Method for Preventing, Reducing, Alleviating or Treating Idiopathic Vomiting
AssigneeThe Iams Company
InventorsJean Soon Park, Ping Hu, Yakang Lin, Lori Ann Reinsalu
Life of this patent
Estimating the term…
Abstract
Compositions containing one or more compounds with inhibitory effect on a 5-HT3a and/or NK-1 receptor are effective for preventing or treating idiopathic vomiting in a mammal.
Claims20
A dietary composition for preventing or treating idiopathic vomiting in a companion animal, comprising one or more compounds in an effective amount for inhibiting a 5-hydroxytryptamine-3a serotonin (5-HT3a) receptor and/or a neurokinin-1 (NK-1) receptor, wherein said one or more compounds are selected from the group consisting of ubiquinone-O (CAS NO. 605-94-7), resveratrol (CAS No. 501-36-0), 1,4-benzenediol, 2,3-dimethyl-(9CI) (CAS NO. 608-43-5), vetiverol (CAS NO. 89-88-3), 3,6-dihydroxyflavone (CAS NO. 92439-20-8), nonivamide (CAS NO. 2444-46-4), DL-palmitoylcarnitine chloride (CAS NO. 6865-14-1), asiatic acid (CAS NO. 464-92-6), farnesal (CAS NO. 19317-11-4), nootkatone (CAS NO. 4674-50-4), alpha-amylcinnamyl alcohol (CAS NO. 101-85-9), delta-dodecalactone (CAS NO. 713-95-1), gamma-dodecalactone (CAS NO. 2305-05-7), alpha-lonone (CAS NO. 127-41-3), biochanin A (CAS NO. 491-80-5), delta-undecalactone (CAS NO. 104-67-6), delta-tetradecalactone (CAS NO. 2721-22-4), 2-(3-phenylpropyl)pyridine (CAS NO. 2110-18-1), 1,14-tetradecanediol (CAS NO. 19812-64-7), (+)-cedrol (CAS NO. 77-53-2), 3-heptyldihydro-5-methyl-2(3H)-furanone (CAS NO. 40923-64-6), delta-undecalactone (CAS NO. 710-04-3), methyl dihydrojasmonate (CAS NO. 24851-98-7), ethoxyquin (CAS NO. 91-53-2), petroselinic acid (CAS NO. 593-39-5), methyl isoeugenol (CAS NO. 93-16-3), vanillyl butyl ether (CAS NO. 82654-98-6), guiaiacwood oil (CAS NO. 8016-23-7), luteolin (CAS NO. 491-70-3), 18-beta-glycyrrhetic acid (CAS NO. 471-53-4), tributyl citrate (CAS NO. 77-94-1), palmitoleic acid (CAS NO. 373-49-9), bisabolol (CAS NO. 515-69-5), curcumin (CAS NO. 458-37-7), piperine (CAS NO. 94-62-2), flavone (CAS NO. 525-82-6), menthoxypropanediol (CAS NO. 87061-04-9), 4-hydroxychalcone (CAS NO. 2657-25-2), N-propyl-4-hydroxybenzoate (CAS NO. 94-13-3), cholecalciferol VD3 (CAS NO. 67-97-0), oleoresin ginger (CAS NO. 8002-60-6), eicosapentaenoic acid (CAS NO. 10417-94-4), riboflavin VB2 (CAS NO. 83-88-5), phloretin (CAS NO. 60-82-2), menadione (CAS NO. 58-27-5), 3,3′-diindolylmethane (CAS NO. 1968-05-4), trans,trans-2,4-heptadienal (CAS NO. 4313-03-5), trans-2,cis-6-nonadienol (CAS NO. 557-48-2), trans,trans-2,4-nonadienal (CAS NO. 5910-87-2), trans-4-methoxycinnamaldehyde (CAS NO. 24680-50-0), 4′-hydroxy-chalcone (CAS NO. 2657-25-2), 2,2′,4′-trihydroxy-chalcone (CAS NO. 26962-50-5), hematoporphyrin dihydrochloride (CAS NO. 17696-69-4), phytosphingosine (CAS NO. 554-62-1), benzylidenacetone (CAS NO. 122-57-6), genistein (CAS NO. 446-72-0), apigenin (CAS NO. 520-36-5), chalcone (CAS NO. 614-47-1), cinnamon bark oil (CAS NO. 8015-91-6), and derivatives and combinations thereof.
A method for preventing or treating idiopathic vomiting in a companion animal, comprising the step of orally administering to said companion animal one or more compounds in an effective amount for inhibiting the 5-hydroxytryptamine-3 (5-HT3) receptor and/or the neurokinin-1 (NK-1) receptor, wherein said one or more compounds are selected from the group consisting of ubiquinone-O (CAS NO. 605-94-7), resveratrol (CAS No. 501-36-0), 1,4-benzenediol, 2,3-dimethyl-(9CI) (CAS NO. 608-43-5), vetiverol (CAS NO. 89-88-3), 3,6-dihydroxyflavone (CAS NO. 92439-20-8), nonivamide (CAS NO. 2444-46-4), DL-palmitoylcarnitine chloride (CAS NO. 6865-14-1), asiatic acid (CAS NO. 464-92-6), farnesal (CAS NO. 19317-11-4), nootkatone (CAS NO. 4674-50-4), alpha-amylcinnamyl alcohol (CAS NO. 101-85-9), delta-dodecalactone (CAS NO. 713-95-1), gamma-dodecalactone (CAS NO. 2305-05-7), alpha-lonone (CAS NO. 127-41-3), biochanin A (CAS NO. 491-80-5), sclareolide (CAS NO. 564-20-5), delta-undecalactone (CAS NO. 104-67-6), delta-tetradecalactone (CAS NO. 2721-22-4), 2-(3-phenylpropyl)pyridine (CAS NO. 2110-18-1), 4′-methoxyflavone (CAS NO. 4143-74-2), (+)-cedrol (CAS NO. 77-53-2), 3-heptyldihydro-5-methyl-2(3H)-furanone (CAS NO. 40923-64-6), delta-undecalactone (CAS NO. 710-04-3), methyl dihydrojasmonate (CAS NO. 24851-98-7), 3,3′-diindolylmethane (CAS NO. 1968-05-4), petroselinic acid (CAS NO. 593-39-5), methyl isoeugenol (CAS NO. 93-16-3), vanillyl butyl ether (CAS NO. 82654-98-6), guiaiacwood oil (CAS NO. 8016-23-7), luteolin (CAS NO. 491-70-3), phloretin (CAS NO. 60-82-2), 18-beta-glycyrrhetic acid (CAS NO. 471-53-4), tributyl citrate (CAS NO. 77-94-1), palmitoleic acid (CAS NO. 373-49-9), baicalein (CAS NO. 491-67-8), piperine (CAS NO. 94-62-2), flavone (CAS NO. 525-82-6), oleic acid (CAS NO. 112-80-1), trans,trans-2,4-heptadienal (CAS NO. 4313-03-5), trans-2,cis-6-nonadienol (CAS NO. 557-48-2), trans,trans-2,4-nonadienal (CAS NO. 5910-87-2), trans-4-methoxycinnamaldehyde (CAS NO. 24680-50-0), beta-ionol (CAS NO. 22029-76-1), betulinic acid (CAS NO. 472-15-1), benzylidenacetone (CAS NO. 122-57-6), genistein (CAS NO. 446-72-0), apigenin (CAS NO. 520-36-5), 4-hydroxychalcone (CAS NO. 2657-25-2), n-Propyl-4-hydroxybenzoate (CAS NO. 94-13-3), and derivatives and combinations thereof.
A composition for preventing or treating idiopathic vomiting in a companion animal, comprising one or more compounds in an effective amount for inhibiting a 5-hydroxytryptamine-3a serotonin (5-HT3a) receptor and/or a neurokinin-1 (NK-1) receptor, wherein said one or more compounds are selected from the group consisting of ubiquinone-O (CAS NO. 605-94-7), resveratrol (CAS No. 501-36-0), 1,4-benzenediol, 2,3-dimethyl-(9CI) (CAS NO. 608-43-5), vetiverol (CAS NO. 89-88-3), 3,6-dihydroxyflavone (CAS NO. 92439-20-8), nonivamide (CAS NO. 2444-46-4), DL-palmitoylcarnitine chloride (CAS NO. 6865-14-1), asiatic acid (CAS NO. 464-92-6), farnesal (CAS NO. 19317-11-4), nootkatone (CAS NO. 4674-50-4), alpha-amylcinnamyl alcohol (CAS NO. 101-85-9), delta-dodecalactone (CAS NO. 713-95-1), gamma-dodecalactone (CAS NO. 2305-05-7), alpha-lonone (CAS NO. 127-41-3), biochanin A (CAS NO. 491-80-5), delta-undecalactone (CAS NO. 104-67-6), delta-tetradecalactone (CAS NO. 2721-22-4), 2-(3-phenylpropyl)pyridine (CAS NO. 2110-18-1), 1,14-tetradecanediol (CAS NO. 19812-64-7), (+)-cedrol (CAS NO. 77-53-2), 3-heptyldihydro-5-methyl-2(3H)-furanone (CAS NO. 40923-64-6), delta-undecalactone (CAS NO. 710-04-3), methyl dihydrojasmonate (CAS NO. 24851-98-7), ethoxyquin (CAS NO. 91-53-2), petroselinic acid (CAS NO. 593-39-5), methyl isoeugenol (CAS NO. 93-16-3), vanillyl butyl ether (CAS NO. 82654-98-6), guiaiacwood oil (CAS NO. 8016-23-7), luteolin (CAS NO. 491-70-3), 18-beta-glycyrrhetic acid (CAS NO. 471-53-4), tributyl citrate (CAS NO. 77-94-1), palmitoleic acid (CAS NO. 373-49-9), bisabolol (CAS NO. 515-69-5), curcumin (CAS NO. 458-37-7), piperine (CAS NO. 94-62-2), flavone (CAS NO. 525-82-6), menthoxypropanediol (CAS NO. 87061-04-9), 4-hydroxychalcone (CAS NO. 2657-25-2), N-propyl-4-hydroxybenzoate (CAS NO. 94-13-3), cholecalciferol VD3 (CAS NO. 67-97-0), oleoresin ginger (CAS NO. 8002-60-6), eicosapentaenoic acid (CAS NO. 10417-94-4), riboflavin VB2 (CAS NO. 83-88-5), phloretin (CAS NO. 60-82-2), menadione (CAS NO. 58-27-5), 3,3′-diindolylmethane (CAS NO. 1968-05-4), trans,trans-2,4-heptadienal (CAS NO. 4313-03-5), trans-2,cis-6-nonadienol (CAS NO. 557-48-2), trans,trans-2,4-nonadienal (CAS NO. 5910-87-2), trans-4-methoxycinnamaldehyde (CAS NO. 24680-50-0), 4′-hydroxy-chalcone (CAS NO. 2657-25-2), 2,2′,4′-trihydroxy-chalcone (CAS NO. 26962-50-5), hematoporphyrin dihydrochloride (CAS NO. 17696-69-4), phytosphingosine (CAS NO. 554-62-1), benzylidenacetone (CAS NO. 122-57-6), genistein (CAS NO. 446-72-0), apigenin (CAS NO. 520-36-5), chalcone (CAS NO. 614-47-1), cinnamon bark oil (CAS NO. 8015-91-6), and derivatives and combinations thereof.
Dependencies are inferred from the claim text.